Logo

PharmaShots Weekly Snapshot (May 20-24, 2019)

Share this

PharmaShots Weekly Snapshot (May 20-24, 2019)


1.BrightInsight Launches a CE-Marked Dosing Calculator for Emicizumab to Treat Patients with Hemophilia A

Published: May 23, 2019 | Tags: BrightInsight, Launches, CE-Marked, Dosing Calculator, Emicizumab, Treat, Patients, Hemophilia A

2. Roche’s Cobas TV/MG Test Receives FDA’s 510 (k) Clearance for the Detection of Sexually Transmitted Diseases

Published: May 23, 2019 | Tags: Roche, Cobas TV/MG Test, Receives, FDA, 510 (k), Clearance, Detection, Sexually Transmitted Diseases

3. Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital Testing in Chlamydia and Gonorrhea

Published: May 23, 2019 | Tags: Hologic, Cepheid, Diagnostic Tests, Receive, 510(k), Clearance, Extragenital Testing, Chlamydia, Gonorrhea

4. Celltrion’s Herzuma (trastuzumab, biosimilar) Receives ANVISA’s Approval for Breast and Gastric Cancer in Brazil

Published: May 23, 2019 | Tags: Celltrion, Herzuma, trastuzumab, biosimilar, Receives, ANVISA, Approval, Brazil

5. GSK’s Shingrix Receives NMPA’s Approval for the Prevention of Shingles in China

Published: May 24, 2019 | Tags: GSK, Shingrix, Receives, NMPA, Approval, Prevention, Shingles, China

6. Boston Scientific Initiates OPTION Study of Watchman FLX Device for Stroke Risk Reduction Post-AF Ablation

Published: May 22, 2019 | Tags: Boston Scientific, Initiates, OPTION, Study, Watchman FLX, Device, Stroke Risk Reduction, Post-AFib Ablation

7. Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Published: May 22, 2019 | Tags: Synlogic, Collaborates, Roche, Evaluate, Combination, SYNB1891, Tecentriq, atezolizumab, Advanced Solid Tumors

8. OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

Published: May 22, 2019 | Tags: OncoSec, Reports, Result, Keytruda, TAVO, P-II, KEYNOTE-890, Study, Refractory, Metastatic, Triple Negative Breast Cancer

9. Santhera Signs an Exclusive License Agreement with Chiesi to Develop and Commercialize Raxone for Leber’s Hereditary Optic Neuropathy

Published: May 23, 2019 | Tags: Santhera, Signs, License Agreement, Chiesi, Develop, Commercialize, Raxone, Leber’s Hereditary Optic Neuropathy

10. Takeda’s Entyvio (vedolizumab) Receives MHLW’s Approval for Moderate to Severely Active Crohn’s Disease in Japan

Published: May 22, 2019 | Tags: Takeda, Entyvio, vedolizumab, Receives, MHLW, Approval, Moderate, Severely, Active, Crohn, Disease, Japan

11. Biocon and Mylan’s Ogivri (trastuzumab, biosimilar) Receives Health Canada’s Approval for HER2-Positive Breast and Gastric Cancers

Published: May 22, 2019 | Tags: Biocon, Mylan, Ogivri, trastuzumab, biosimilar, Receives, Health Canada, Approval, HER2-Positive, Breast,Gastric Cancers

12. Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Published: May 22, 2019 | Tags: Medtronic, Reports, Results, Symplicity Renal Denervation System, Two Studies, Hypertensive Heart Diseases

13. Abbott Reports Results of Minimally Invasive Device in TRILUMINATE Study for Tricuspid Heart Valve Leaks

Published: May 21, 2019 | Tags: Abbott, Reports, Results, Minimally Invasive Device, TRILUMINATE, Study, Tricuspid Heart Valve Leaks

14. Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer

Published: May 21, 2019 | Tags: Array BioPharma, Reports, Results, Combination Therapy, P-III, BEACON, CRC, Study, BRAFV600E Mutant, Metastatic Colorectal Cancer

15. Verily Collaborates with Global Pharma Companies to Develop Clinical Research Program

Published: May 21, 2019 | Tags: Verily, Collaborates, Big Pharma, Companies, Develop, Clinical Research Program

16. Merck to Acquire Peloton Therapeutics for $2.2B

Published: May 21, 2019 | Tags: Merck, Acquire, Peloton Therapeutics, $2.2B

17.Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Published: May 21, 2019 | Tags: Clovis Oncology, Reports, Results, Rubraca, rucaparib, P-III, ARIEL3, Study, Advanced, Ovarian Cancer

18. AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START Study for Mild Asthma

Published: May 20, 2019 | Tags: AstraZeneca, Reports, Results, Symbicort Turbuhaler, budesonide, formoterol, Novel START Study, Mild Asthma

19. Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer

Published: May 20, 2019 | Tags: Merck, Reports, Results, Keytruda, pembrolizumab, P-III, KEYNOTE-119, Study, Metastatic, Triple-Negative Breast Cancer

20. Santhera Signs a Pre-Clinical Research Agreement with Biozentrum to Advance Gene Therapy for Congenital Muscular Dystrophy

Published: May 20, 2019 | Tags: Santhera, Signs, Pre-Clinical, Research, Agreement, Biozentrum, Advance, Gene Therapy, Congenital Muscular Dystrophy

21. UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of Seizure Cluster in Epilepsy in the US

Published: May 20, 2019 | Tags: UCB, Nayzilam, midazolam, Receives, FDA, Approval, Treatment, Seizure Cluster, Epilepsy

22. Takeda’s Gattex (teduglutide) Receives the US FDA’s Approval for Short Bowel Syndrome in Children

Published: May 17, 2019 | Tags: Takeda, Gattex, teduglutide, Receives, US FDA, Approval, Short Bowel Syndrome, Children

23. Ethicon (J&J) Recalls Endo-Surgery Intraluminal Staplers Due to Complete Staple Line Failure

Published: May 16, 2019 | Tags: Ethicon, J&J, Recalls, Endo, Surgery, Intraluminal Staplers, Complete, Staple, Line Failure

24. Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

Published: May 19, 2019 | Tags: Takeda, Reports, Results, Entyvio, vedolizumab, P-III, VARSITY, Study, Ulcerative Colitis

25. AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

Published: May 17, 2019 | Tags: AbbVie, Reports, Results, Depatux-M, depatuxizumab mafodotin, P-III, INTELLANCE-1, Study, Glioblastoma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions